1 EXECUTIVE SUMMARY
1.1 MARKET SYNOPSIS 16
1.2 MARKET ATTRACTIVENESS ANALYSIS 17
1.3 GLOBAL BIOMARKERS MARKET, BY PRODUCT 17
1.4 GLOBAL BIOMARKERS MARKET, BY TYPE 18
1.5 GLOBAL BIOMARKERS MARKET, BY APPLICATION 19
1.6 GLOBAL BIOMARKERS MARKET, BY DISEASE INDICATION 20
2 MARKET INTRODUCTION
2.1 DEFINITION 21
2.2 SCOPE OF THE STUDY 21
2.3 RESEARCH OBJECTIVE 21
2.4 MARKET STRUCTURE 21
2.5 ASSUMPTIONS & LIMITATIONS 22
3 RESEARCH METHODOLOGY
3.1 DATA MINING 23
3.2 SECONDARY RESEARCH 23
3.3 PRIMARY RESEARCH 25
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 26
3.5 FORECASTING TECHNIQUES 26
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 27
3.6.1 BOTTOM-UP APPROACH 28
3.6.2 TOP-DOWN APPROACH 28
3.7 DATA TRIANGULATION 29
3.8 VALIDATION 29
4 MARKET DYNAMICS
4.1 OVERVIEW 30
4.2 DRIVERS 31
4.2.1 HIGH PREVALENCE OF CANCER 31
4.2.2 INCREASING APPLICATIONS AND ADVANCEMENTS OF BIOMARKERS 31
4.2.3 INCREASING PRODUCT LAUNCHES BY MAJOR PLAYERS 32
4.3 RESTRAINTS 33
4.3.1 HIGH CAPITAL INVESTMENT 33
4.4 OPPORTUNITIES 33
4.4.1 INCORPORATION OF ARTIFICIAL INTELLIGENCE (AI) IN THE BIOMARKER TECHNOLOGY 33
5 MARKET FACTOR ANALYSIS
5.1 PORTERโS FIVE FORCES MODEL 34
5.1.1 BARGAINING POWER OF SUPPLIERS 34
5.1.2 BARGAINING POWER OF BUYERS 35
5.1.3 THREAT OF NEW ENTRANTS 35
5.1.4 THREAT OF SUBSTITUTES 35
5.1.5 INTENSITY OF RIVALRY 35
5.2 VALUE CHAIN ANALYSIS 36
5.2.1 R&D AND DESIGNING 37
5.2.2 MANUFACTURING 37
5.2.3 DISTRIBUTION, MARKETING, AND SALES 37
5.2.4 POST-SALES MONITORING 37
6 BIOMARKERS MARKET, BY PRODUCT
6.1 OVERVIEW 38
6.2 CONSUMABLES 39
6.3 SERVICES 40
6.4 SOFTWARE 41
7 BIOMARKERS MARKET, BY TYPE
7.1 OVERVIEW 42
7.2 SAFETY BIOMARKERS 44
7.3 EFFICACY BIOMARKERS 44
7.4 VALIDATION BIOMARKERS 45
8 BIOMARKERS MARKET, BY APPLICATION
8.1 OVERVIEW 46
8.2 DIAGNOSTICS 47
8.3 PERSONALIZED MEDICINE 48
8.4 DRUG DISCOVERY AND DEVELOPMENT 49
8.5 DISEASE RISK ASSESSMENT 49
9 BIOMARKERS MARKET, BY DISEASE INDICATION
9.1 OVERVIEW 51
9.2 CANCER 53
9.3 NEUROLOGICAL DISORDERS 53
9.4 CARDIOVASCULAR DISORDERS 54
9.5 IMMUNOLOGICAL DISORDERS 55
10 GLOBAL BIOMARKERS MARKET, BY REGION
10.1 OVERVIEW 56
10.2 AMERICAS 58
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
10.2.1 NORTH AMERICA 61
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
10.2.1.1 US 64
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
10.2.1.2 CANADA 66
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
10.2.2 LATIN AMERICA 68
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
10.3 EUROPE 70
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
10.3.1 WESTERN EUROPE 73
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
10.3.1.1 GERMANY 74
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
10.3.1.2 UK 76
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
10.3.1.3 FRANCE 77
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
10.3.1.4 ITALY 79
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
10.3.1.5 SPAIN 81
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
10.3.1.6 REST OF WESTERN EUROPE 82
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
10.3.2 EASTERN EUROPE 84
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
10.4 ASIA-PACIFIC 86
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
10.4.1 CHINA 89
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
10.4.2 JAPAN 90
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
10.4.3 INDIA 92
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
10.4.4 AUSTRALIA 94
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
10.4.5 SOUTH KOREA 95
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
10.4.6 REST OF ASIA-PACIFIC 97
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
10.5 MIDDLE EAST & AFRICA 99
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
10.5.1 MIDDLE EAST 101
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
10.5.2 AFRICA 103
BIOMARKERS MARKET, BY PRODUCT
BIOMARKERS MARKET, BY TYPE
BIOMARKERS MARKET, BY APPLICATION
BIOMARKERS MARKET, BY DISEASE INDICATION
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW 105
11.2 COMPETITIVE BENCHMARKING 106
11.3 GLOBAL BIOMARKERS MARKET: COMPANY RANKING 107
11.4 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 108
11.5 MAJOR GROWTH STRATEGY IN THE GLOBAL BIOMARKERS MARKET 108
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 109
11.6.1 NEW PRODUCT LAUNCHES AND APPROVALS 109
11.6.2 JOINT VENTURES 110
11.6.3 EXPANSIONS 111
11.6.4 ACQUISITIONS 111
12 COMPANY PROFILES
12.1 MESO SCALE DIAGNOSTICS, LLC 112
12.1.1 COMPANY OVERVIEW 112
12.1.2 FINANCIAL OVERVIEW 112
12.1.3 PRODUCTS/SERVICES OFFERED 112
12.1.4 KEY DEVELOPMENTS 112
12.1.5 SWOT ANALYSIS 113
12.1.6 KEY STRATEGIES 113
12.2 THERMO FISHER SCIENTIFIC INC. 114
12.2.1 COMPANY OVERVIEW 114
12.2.2 FINANCIAL OVERVIEW 114
12.2.3 PRODUCTS/SERVICES OFFERED 115
12.2.4 KEY DEVELOPMENTS 115
12.2.5 SWOT ANALYSIS 116
12.2.6 KEY STRATEGIES 116
12.3 BIO-RAD LABORATORIES, INC. 117
12.3.1 COMPANY OVERVIEW 117
12.3.2 FINANCIAL OVERVIEW 117
12.3.3 PRODUCTS/SERVICES OFFERED 118
12.3.4 KEY DEVELOPMENTS 118
12.3.5 SWOT ANALYSIS 118
12.3.6 KEY STRATEGIES 119
12.4 CISBIO 120
12.4.1 COMPANY OVERVIEW 120
12.4.2 FINANCIAL OVERVIEW 120
12.4.3 PRODUCTS/SERVICES OFFERED 121
12.4.4 KEY DEVELOPMENTS 121
12.4.5 SWOT ANALYSIS 122
12.4.6 KEY STRATEGIES 122
12.5 EKF DIAGNOSTICS 123
12.5.1 COMPANY OVERVIEW 123
12.5.2 FINANCIAL OVERVIEW 123
12.5.3 PRODUCTS/SERVICES OFFERED 124
12.5.4 KEY DEVELOPMENTS 124
12.5.5 SWOT ANALYSIS 125
12.5.6 KEY STRATEGIES 125
12.6 QIAGEN N. V. 126
12.6.1 COMPANY OVERVIEW 126
12.6.2 FINANCIAL OVERVIEW 126
12.6.3 PRODUCTS/SERVICES OFFERED 127
12.6.4 KEY DEVELOPMENTS 127
12.6.5 SWOT ANALYSIS 128
12.6.6 KEY STRATEGIES 128
12.7 ABBOTT LABORATORIES 129
12.7.1 COMPANY OVERVIEW 129
12.7.2 FINANCIAL OVERVIEW 129
12.7.3 PRODUCTS/SERVICES OFFERED 130
12.7.4 ABBOTT LABORATORIES: KEY DEVELOPMENTS 130
12.7.5 SWOT ANALYSIS 131
12.7.6 KEY STRATEGIES 131
12.8 ENZO BIOCHEM INC. 132
12.8.1 COMPANY OVERVIEW 132
12.8.2 FINANCIAL OVERVIEW 132
12.8.3 PRODUCTS/SERVICES OFFERED 133
12.8.4 KEY DEVELOPMENTS 133
12.8.5 SWOT ANALYSIS 134
12.8.6 KEY STRATEGIES 134
12.9 SIGNOSIS 135
12.9.1 COMPANY OVERVIEW 135
12.9.2 FINANCIAL OVERVIEW 135
12.9.3 PRODUCTS/SERVICES OFFERED 135
12.9.4 KEY DEVELOPMENTS 135
12.9.5 SWOT ANALYSIS 136
12.9.6 KEY STRATEGIES 136
12.10 PERKINELMER INC. 137
12.10.1 COMPANY OVERVIEW 137
12.10.2 FINANCIAL OVERVIEW 137
12.10.3 PRODUCTS/SERVICES OFFERED 138
12.10.4 KEY DEVELOPMENTS 138
12.10.5 SWOT ANALYSIS 138
12.10.6 KEY STRATEGIES 138
12.11 MERCK KGAA 139
12.11.1 COMPANY OVERVIEW 139
12.11.2 FINANCIAL OVERVIEW 139
12.11.3 PRODUCTS/SERVICES OFFERED 140
12.11.4 KEY DEVELOPMENTS 140
12.11.5 SWOT ANALYSIS 141
12.11.6 KEY STRATEGIES 141
12.12 F. HOFFMANN-LA ROCHE LTD 142
12.12.1 COMPANY OVERVIEW 142
12.12.2 FINANCIAL OVERVIEW 142
12.12.3 PRODUCTS/SERVICES OFFERED 143
12.12.4 KEY DEVELOPMENTS 143
12.12.5 SWOT ANALYSIS 144
12.12.6 KEY STRATEGIES 144
13 APPENDIX
13.1 REFERENCES 145
13.2 RELATED REPORTS 146
14 LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS 22
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 25
TABLE 3 GLOBAL BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 39
TABLE 4 GLOBAL BIOMARKERS MARKET FOR CONSUMABLES, BY REGION, 2020โ2027 (USD MILLION) 40
TABLE 5 GLOBAL BIOMARKERS MARKET FOR SERVICES, BY REGION, 2020โ2027 (USD MILLION) 41
TABLE 6 GLOBAL BIOMARKERS MARKET FOR SOFTWARE, BY REGION, 2020โ2027 (USD MILLION) 41
TABLE 7 GLOBAL BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 43
TABLE 8 GLOBAL BIOMARKERS MARKET FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 43
TABLE 9 GLOBAL BIOMARKERS MARKET FOR SAFETY BIOMARKERS, BY REGION, 2020โ2027 (USD MILLION) 44
TABLE 10 GLOBAL BIOMARKERS MARKET FOR EFFICACY BIOMARKERS, BY REGION, 2020โ2027 (USD MILLION) 45
TABLE 11 GLOBAL BIOMARKERS MARKET FOR VALIDATION BIOMARKERS, BY REGION, 2020โ2027 (USD MILLION) 45
TABLE 12 GLOBAL BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 47
TABLE 13 GLOBAL BIOMARKERS MARKET FOR DIAGNOSTICS, BY REGION, 2020โ2027 (USD MILLION) 48
TABLE 14 GLOBAL BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2020โ2027 (USD MILLION) 48
TABLE 15 GLOBAL BIOMARKERS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2020โ2027 (USD MILLION) 49
TABLE 16 GLOBAL BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY REGION, 2020โ2027 (USD MILLION) 50
TABLE 17 GLOBAL BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 52
TABLE 18 GLOBAL BIOMARKERS MARKET FOR CANCER, BY REGION, 2020โ2027 (USD MILLION) 53
TABLE 19 GLOBAL BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2020โ2027 (USD MILLION) 54
TABLE 20 GLOBAL BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2020โ2027 (USD MILLION) 54
TABLE 21 GLOBAL BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2020โ2027 (USD MILLION) 55
TABLE 22 GLOBAL BIOMARKERS MARKET, BY REGION, 2020โ2027 (USD MILLION) 57
TABLE 23 AMERICAS: BIOMARKERS MARKET, BY REGION, 2020โ2027 (USD MILLION) 59
TABLE 24 AMERICAS: BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 59
TABLE 25 AMERICAS: BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 59
TABLE 26 AMERICAS: BIOMARKERS MARKET FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 60
TABLE 27 AMERICAS: BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 60
TABLE 28 AMERICAS: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 61
TABLE 29 NORTH AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2020โ2027 (USD MILLION) 61
TABLE 30 NORTH AMERICA: BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 62
TABLE 31 NORTH AMERICA: BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 62
TABLE 32 NORTH AMERICA: BIOMARKERS MARKET FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 62
TABLE 33 NORTH AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 63
TABLE 34 NORTH AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 63
TABLE 35 US: BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 64
TABLE 36 US: BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 64
TABLE 37 US: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 64
TABLE 38 US: BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 65
TABLE 39 US: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 65
TABLE 40 CANADA: BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 66
TABLE 41 CANADA: BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 66
TABLE 42 CANADA: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 66
TABLE 43 CANADA: BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 67
TABLE 44 CANADA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 67
TABLE 45 LATIN AMERICA: BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 68
TABLE 46 LATIN AMERICA: BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 68
TABLE 47 LATIN AMERICA: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 68
TABLE 48 LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 69
TABLE 49 LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 69
TABLE 50 EUROPE: BIOMARKERS MARKET, BY REGION, 2020โ2027 (USD MILLION) 71
TABLE 51 EUROPE: BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 71
TABLE 52 EUROPE: BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 71
TABLE 53 EUROPE: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 72
TABLE 54 EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 72
TABLE 55 EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 73
TABLE 56 WESTERN EUROPE: BIOMARKERS MARKET, BY COUNTRY, 2020โ2027 (USD MILLION) 74
TABLE 57 GERMANY: BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 74
TABLE 58 GERMANY: BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 74
TABLE 59 GERMANY: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 75
TABLE 60 GERMANY: BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 75
TABLE 61 GERMANY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 75
TABLE 62 UK: BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 76
TABLE 63 UK: BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 76
TABLE 64 UK: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 76
TABLE 65 UK: BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 77
TABLE 66 UK: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 77
TABLE 67 FRANCE: BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 77
TABLE 68 FRANCE: BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 78
TABLE 69 FRANCE: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 78
TABLE 70 FRANCE: BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 78
TABLE 71 FRANCE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 79
TABLE 72 ITALY: BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 79
TABLE 73 ITALY: BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 79
TABLE 74 ITALY: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 80
TABLE 75 ITALY: BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 80
TABLE 76 ITALY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 80
TABLE 77 SPAIN: BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 81
TABLE 78 SPAIN: BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 81
TABLE 79 SPAIN: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 81
TABLE 80 SPAIN: BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 82
TABLE 81 SPAIN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 82
TABLE 82 REST OF WESTERN EUROPE: BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 82
TABLE 83 REST OF WESTERN EUROPE: BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 83
TABLE 84 REST OF WESTERN EUROPE: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 83
TABLE 85 REST OF WESTERN EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 83
TABLE 86 REST OF WESTERN EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 84
TABLE 87 EASTERN EUROPE: BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 84
TABLE 88 EASTERN EUROPE: BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 84
TABLE 89 EASTERN EUROPE: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 85
TABLE 90 EASTERN EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 85
TABLE 91 EASTERN EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 85
TABLE 92 ASIA-PACIFIC: BIOMARKERS MARKET, BY COUNTRY, 2020โ2027 (USD MILLION) 87
TABLE 93 ASIA-PACIFIC: BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 87
TABLE 94 ASIA-PACIFIC: BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 87
TABLE 95 ASIA-PACIFIC: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 88
TABLE 96 ASIA-PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 88
TABLE 97 ASIA-PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 88
TABLE 98 CHINA: BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 89
TABLE 99 CHINA: BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 89
TABLE 100 CHINA: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 89
TABLE 101 CHINA: BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 90
TABLE 102 CHINA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 90
TABLE 103 JAPAN: BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 90
TABLE 104 JAPAN: BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 91
TABLE 105 JAPAN: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 91
TABLE 106 JAPAN: BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 91
TABLE 107 JAPAN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 92
TABLE 108 INDIA: BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 92
TABLE 109 INDIA: BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 92
TABLE 110 INDIA: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 93
TABLE 111 INDIA: BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 93
TABLE 112 INDIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 93
TABLE 113 AUSTRALIA: BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 94
TABLE 114 AUSTRALIA: BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 94
TABLE 115 AUSTRALIA: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 94
TABLE 116 AUSTRALIA: BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 95
TABLE 117 AUSTRALIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 95
TABLE 118 SOUTH KOREA: BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 95
TABLE 119 SOUTH KOREA: BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 96
TABLE 120 SOUTH KOREA: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 96
TABLE 121 SOUTH KOREA: BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 96
TABLE 122 SOUTH KOREA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 97
TABLE 123 REST OF ASIA-PACIFIC: BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 97
TABLE 124 REST OF ASIA-PACIFIC: BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 97
TABLE 125 REST OF ASIA-PACIFIC: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 98
TABLE 126 REST OF ASIA-PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 98
TABLE 127 REST OF ASIA-PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 98
TABLE 128 MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY REGION, 2020โ2027 (USD MILLION) 99
TABLE 129 MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 100
TABLE 130 MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 100
TABLE 131 MIDDLE EAST & AFRICA: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 100
TABLE 132 MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 101
TABLE 133 MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 101
TABLE 134 MIDDLE EAST: BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 101
TABLE 135 MIDDLE EAST: BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 102
TABLE 136 MIDDLE EAST: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 102
TABLE 137 MIDDLE EAST: BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 102
TABLE 138 MIDDLE EAST: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 103
TABLE 139 AFRICA: BIOMARKERS MARKET, BY PRODUCT, 2020โ2027 (USD MILLION) 103
TABLE 140 AFRICA: BIOMARKERS MARKET, BY TYPE, 2020โ2027 (USD MILLION) 103
TABLE 141 AFRICA: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020โ2027 (USD MILLION) 104
TABLE 142 AFRICA: BIOMARKERS MARKET, BY APPLICATION, 2020โ2027 (USD MILLION) 104
TABLE 143 AFRICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020โ2027 (USD MILLION) 104
TABLE 144 MAJOR MANUFACTURERS RANKING, 2020 107
TABLE 145 TOP PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE BIOMARKERS MARKET 108
TABLE 146 NEW PRODUCT LAUNCHES AND APPROVALS 109
TABLE 147 JOINT VENTURES 110
TABLE 148 EXPANSIONS 111
TABLE 149 ACQUISITIONS 111
TABLE 150 MESO SCALE DIAGNOSTICS, LLC: PRODUCTS/SERVICES OFFERED 112
TABLE 151 MESO SCALE DIAGNOSTICS, LLC: KEY DEVELOPMENTS 112
TABLE 152 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 115
TABLE 153 THERMO FISHER SCIENTIFIC INC.: KEY DEVELOPMENTS 115
TABLE 154 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED 118
TABLE 155 BIO-RAD LABORATORIES, INC.: KEY DEVELOPMENTS 118
TABLE 156 CISBIO: PRODUCTS/SERVICES OFFERED 121
TABLE 157 EKF DIAGNOSTICS: PRODUCTS/SERVICES OFFERED 124
TABLE 158 EKF DIAGNOSTICS: KEY DEVELOPMENTS 124
TABLE 159 QIAGEN: PRODUCTS/SERVICES OFFERED 127
TABLE 160 QIAGEN: KEY DEVELOPMENTS 127
TABLE 161 ABBOTT LABORATORIES: PRODUCTS/SERVICES OFFERED 130
TABLE 162 KEY DEVELOPMENTS 130
TABLE 163 ENZO BIOCHEM INC.: PRODUCTS/SERVICES OFFERED 133
TABLE 164 ENZO BIOCHEM INC.: KEY DEVELOPMENTS 133
TABLE 165 SIGNOSIS: PRODUCTS/SERVICES OFFERED 135
TABLE 166 PERKINELMER INC.: PRODUCTS/SERVICES OFFERED 138
TABLE 167 MERCK KGAA: PRODUCTS/SERVICES OFFERED 140
TABLE 168 MERCK KGAA: KEY DEVELOPMENTS 140
TABLE 169 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED 143
TABLE 170 F. HOFFMANN-LA ROCHE LTD: KEY DEVELOPMENTS 143
15 LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS 16
FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS (2020) 17
FIGURE 3 GLOBAL BIOMARKERS MARKET, BY PRODUCT 17
FIGURE 4 GLOBAL BIOMARKERS MARKET, BY TYPE 18
FIGURE 5 GLOBAL BIOMARKERS MARKET, BY APPLICATION 19
FIGURE 6 GLOBAL BIOMARKERS MARKET, BY DISEASE INDICATION 20
FIGURE 7 GLOBAL BIOMARKERS MARKET STRUCTURE 21
FIGURE 8 BOTTOM-UP AND TOP-DOWN APPROACHES 28
FIGURE 9 MARKET DYNAMICS ANALYSIS: GLOBAL BIOMARKERS MARKET 30
FIGURE 10 DRIVERS: IMPACT ANALYSIS 32
FIGURE 11 RESTRAINTS: IMPACT ANALYSIS 33
FIGURE 12 PORTERโS FIVE FORCES ANALYSIS: GLOBAL BIOMARKERS MARKET 34
FIGURE 13 VALUE CHAIN ANALYSIS OF THE GLOBAL BIOMARKERS MARKET 36
FIGURE 14 GLOBAL BIOMARKERS MARKET, BY PRODUCT, 2020 (%) 38
FIGURE 15 GLOBAL BIOMARKERS MARKET, BY PRODUCT, 2020 & 2027 (USD MILLION) 39
FIGURE 16 GLOBAL BIOMARKERS MARKET, BY TYPE, 2020 (%) 42
FIGURE 17 GLOBAL BIOMARKERS MARKET, BY TYPE, 2020 & 2027 (USD MILLION) 43
FIGURE 18 GLOBAL BIOMARKERS MARKET, BY APPLICATION, 2020 (%) 46
FIGURE 19 GLOBAL BIOMARKERS MARKET, BY APPLICATION, 2020 & 2027 (USD MILLION) 47
FIGURE 20 GLOBAL BIOMARKERS MARKET, BY DISEASE INDICATION, 2020 (%) 51
FIGURE 21 GLOBAL BIOMARKERS MARKET, BY DISEASE INDICATION, 2020 & 2027 (USD MILLION) 52
FIGURE 22 GLOBAL BIOMARKERS MARKET, BY REGION, 2020 (%) 56
FIGURE 23 GLOBAL BIOMARKERS MARKET, BY REGION, 2020 & 2027 (USD MILLION) 56
FIGURE 24 AMERICAS: BIOMARKERS MARKET, BY REGION, 2020 (%) 58
FIGURE 25 NORTH AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2020 (%) 61
FIGURE 26 EUROPE: BIOMARKERS MARKET, BY REGION, 2020 (%) 70
FIGURE 27 WESTERN EUROPE: BIOMARKERS MARKET, BY COUNTRY, 2020 (%) 73
FIGURE 28 ASIA-PACIFIC: BIOMARKERS MARKET, BY COUNTRY, 2020 (%) 86
FIGURE 29 MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY REGION, 2020 (%) 99
FIGURE 30 BENCHMARKING OF MAJOR COMPETITORS 106
FIGURE 31 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL BIOMARKERS MARKET 108
FIGURE 32 MESO SCALE DIAGNOSTICS, LLC: SWOT ANALYSIS 113
FIGURE 33 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT 114
FIGURE 34 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS 116
FIGURE 35 BIO-RAD LABORATORIES, INC.: FINANCIAL OVERVIEW SNAPSHOT 117
FIGURE 36 BIO-RAD LABORATORIES, INC: SWOT ANALYSIS 118
FIGURE 37 CISBIO: FINANCIAL OVERVIEW SNAPSHOT 120
FIGURE 38 CISBIO: SWOT ANALYSIS 122
FIGURE 39 EKF DIAGNOSTICS: FINANCIAL OVERVIEW SNAPSHOT 123
FIGURE 40 EKF DIAGNOSTICS: SWOT ANALYSIS 125
FIGURE 41 QIAGEN: FINANCIAL OVERVIEW SNAPSHOT 126
FIGURE 42 QIAGEN: SWOT ANALYSIS 128
FIGURE 43 ABBOTT LABORATORIES: FINANCIAL OVERVIEW SNAPSHOT 129
FIGURE 44 ABBOTT LABORATORIES: SWOT ANALYSIS 131
FIGURE 45 ENZO BIOCHEM INC.: FINANCIAL OVERVIEW SNAPSHOT 132
FIGURE 46 ENZO BIOCHEM INC.: SWOT ANALYSIS 134
FIGURE 47 SIGNOSIS: SWOT ANALYSIS 136
FIGURE 48 PERKINELMER INC.: FINANCIAL OVERVIEW SNAPSHOT 137
FIGURE 49 PERKINELMER INC.: SWOT ANALYSIS 138
FIGURE 50 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT 139
FIGURE 51 MERCK KGAA: SWOT ANALYSIS 141
FIGURE 52 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT 142
FIGURE 53 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS 144
